Antibodies directed to the receptor tyrosine kinase c-Met
US9169329B2 · kind B2 · utility
5Cited by
0References
20Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jun 1, 2011 |
| Grant date | Oct 27, 2015 |
| Priority date | — |
| Expiry date | Sep 23, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to antibodies that specifically bind to unprocessed c-Met present on the surface of tumor cells. These antibodies are useful in the diagnosis and treatment of cancer or as agents for delivering moieties to cancer cells. The antibodies of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.